We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

61 hedge funds and large institutions have $26.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 23 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less capital invested

Capital invested by funds: $27.5M → $26.7M (-$846K)

9% less funds holding

Funds holding: 67 → 61 (-6)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

65% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 23

Holders
61
Holders Change
-6
Holders Change %
-8.96%
% of All Funds
1.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
23
Closed
13
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
-$11K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$601K
2
Deutsche Bank
Deutsche Bank
Germany
+$155K
3
PAM
Panagora Asset Management
Massachusetts
+$29.8K
4
UBS Group
UBS Group
Switzerland
+$28.4K
5
FNYS
First New York Securities
New York
+$19.3K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.42M
2
Millennium Management
Millennium Management
New York
-$792K
3
PP
Paloma Partners
Connecticut
-$292K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$268K
5
CS
Credit Suisse
Switzerland
-$153K
Name Holding Trade Value Shares
Change 		Change in
Stake
FANJ
51
Financial Architects (New Jersey)
New Jersey
$2K – – –
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K – – –
Bank of America
53
Bank of America
North Carolina
$1K -$35.7K -9,792 -98%
PP
54
Paloma Partners
Connecticut
– -$292K -85,992 Closed
Alyeska Investment Group
55
Alyeska Investment Group
Illinois
– -$268K -78,949 Closed
LP
56
LMR Partners
United Kingdom
– -$80K -23,505 Closed
AGM
57
Alpine Global Management
New York
– -$60K -17,559 Closed
LCM
58
Laurion Capital Management
New York
– -$55K -16,131 Closed
Squarepoint
59
Squarepoint
New York
– -$32K -9,370 Closed
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
– -$15K -4,377 Closed
BCM
61
Bayesian Capital Management
New York
– -$6K -1,620 Closed
FHC
62
First Heartland Consultants
Missouri
– -$5 -1,492 Closed
OMC
63
Old Mission Capital
Illinois
– -$5K -1,337 Closed
MFS
64
MSI Financial Services
Massachusetts
– -$47 -13 -87%
Citigroup
65
Citigroup
New York
– -$36 -10 -7%
LYV
66
Live Your Vision
Pennsylvania
– +$25 +7 New
1 2
3

CTIC Hedge Fund Activity: Q3 2016 in Review

61 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2016, worth a combined $26.7M — down 3.1% from $27.5M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CTIC and 8 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 8 added.

The largest buyer was Renaissance Technologies, adding an estimated $601K. The largest seller was Fidelity Investments, cutting an estimated $2.42M.

  • 61 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2016, down from 67 in Q2 2016.
  • Funds reported $26.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2016, down 3.1% quarter-over-quarter.
  • 8 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2016 and 13 closed out, a net change of -5 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $601K added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2016 was Fidelity Investments, an estimated $2.42M sold.

Based on aggregated 13F filings for Q3 2016.